Financial information

Financial information

CRV’s turnover increased by 1 percent in the 2019-2020 financial year compared with the 2018-2019 financial year, before payment of the dividend and at the current exchange rates.

We have seen sales increase in the financial year in all markets with the exception of the USA. In the Dutch market we have benefited from a modest increase in herd numbers compared with the previous financial year. The negative impact of the crisis caused by coronavirus on the turnover was limited. Turnover in MPR and exports from the Netherlands in particular fell due to travel restrictions, among other things.

The operating result is slightly lower than last year due to three factors. The margin was positively influenced by higher sales of genetic material and higher sales of data products. As a result of COVID-19, travelling expenses were a far lower cost item than in the previous year. Finally, this year, in comparison with the previous year, higher investments were made in research projects, specifically Engender. The operating result for the financial year was €2.2 million (previous financial year €5.3 million).


Key figures

2019-2020
(x €1,000)

2018-2019
(x €1,000)

2017-2018
(x €1,000)

2016-2017
(x €1,000)

2015-2016
(x €1,000)

Net sales before member dividend

168,743

166,873

173,573

171,901

170,244

Member dividend

-346

0

-4,148

-4,098

-1,941

Net sales after member dividend

168,397

166,873

169,425

167,803

168,303

Operating profit (including book profits)

2,060

5,349

10,617

10,136

6,991

Goodwill amortisation, impairments and restructuring

-1,358

-970

-623

347

-3,249

Member dividend

-346

0

-4,148

-4,098

-1,941

Operating result

356

4,379

5,846

6,385

1,801

Result after taxation

346

3,758

4,148

4,098

1.940

Equity capital

83,703

87,233

83,759

82,804

79,481

Balance sheet total

120,878

124,072

123,771

121,792

119,884

Working capital (including cash and cash equivalents)

30,705

30,430

37,475

33,926

39,982

Liquidity

1.93

1.93

2.05

1.98

2.16

Solvency

69%

70%

68%

68%

66%


The table above shows CRV’s development over the past five financial years. To enable good comparison, the key figures are shown including and excluding the payment of dividends to members and the amortisation of goodwill. In the event of an acquisition, goodwill is the added value of a company over and above its net worth. Goodwill amortisation is the reduction in the amount of the goodwill asset.

Key figures

2019-2020
(x €1,000)

2018-2019
(x €1,000)

2017-2018
(x €1,000)

2016-2017
(x €1,000)

2015-2016
(x €1,000)

Net sales before member dividend

168,743

166,873

173,573

171,901

170,244

Member dividend

-346

0

-4,148

-4,098

-1,941

Net sales after member dividend

168,397

166,873

169,425

167,803

168,303

Operating profit (including book profits)

2,060

5,349

10,617

10,136

6,991

Goodwill amortisation, impairments and restructuring

-1,358

-970

-623

347

-3,249

Member dividend

-346

0

-4,148

-4,098

-1,941

Operating result

356

4,379

5,846

6,385

1,801

Result after taxation

346

3,758

4,148

4,098

1.940

Equity capital

83,703

87,233

83,759

82,804

79,481

Balance sheet total

120,878

124,072

123,771

121,792

119,884

Working capital (including cash and cash equivalents)

30,705

30,430

37,475

33,926

39,982

Liquidity

1.93

1.93

2.05

1.98

2.16

Solvency

69%

70%

68%

68%

66%


The table above shows CRV’s development over the past five financial years. To enable good comparison, the key figures are shown including and excluding the payment of dividends to members and the amortisation of goodwill. In the event of an acquisition, goodwill is the added value of a company over and above its net worth. Goodwill amortisation is the reduction in the amount of the goodwill asset.